Tumor immunotherapy
Estimation of the Domain of Attraction of Free Tumor Equilibrium Point for Perturbed Tumor Immunotherapy Model
... perturbed tumor immunotherapy model in Section 2 which is selected from non-polynomial nonlinear systems of such models, and compared with other models, it describes the behavior of tumor cells ...
6
Antibody carriers of CpG oligodeoxynucleotides for solid tumor immunotherapy
... solid tumor immunotherapy 1 warranted further study to establish additional means of administration and to elucidate mechanistic immune ...DNP-immunized, tumor-bearing ...in tumor tissue, ...
115
Review Article Targeting complement regulatory proteins in tumor immunotherapy
... helps tumor cells escape immune attacks and leads to the poor prognosis of patients with ...on tumor cells limit the therapeutic efficacy of mAbs in tumor ...in tumor immunity, T cell response ...
12
Progress in research on paclitaxel and tumor immunotherapy
... Tumor immunotherapy produces an immune response to tumors by improving the body’s ...kills tumor cells and regulates various immune cells, such as ef- fector T cells, dendritic cells (DCs), natural ...
11
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
... as tumor mouse models exhibit co-expression of PD-1 and LAG-3 on tumor-infiltrating T cells (TILs) [90, ...or tumor growth, pointing out the complex interac- tions among inhibitory receptors, whereby ...
16
MR imaging in an experimental model of brain tumor immunotherapy
... KHT murine sarcoma was stereotaxically implanted into the right frontal lobe of C3HfHeN mice at doses of 10,000 and 50,000 tumor cells.. The KHT sarcoma is 100% fatal in untreated mice.[r] ...
6
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
... and tumor data should be ...the tumor should also be performed with special emphasis on identifying mutations in ...lowing immunotherapy should also be reassessed for pos- sible resection [42, ...
23
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
... Subsequent to CTLA-4, PD-1 was also shown to regulate the immune response. PD-1 interacts with B7-homolog 1 (B7-H1 or programmed death receptor-1 ligand1 [PD-L1]) and B7-DC (PD-L2) on APCs and tumor cells. ...
9
Toward integrative cancer immunotherapy: targeting the tumor microenvironment
... deliver tumor antigen-specific effector cells by adoptive cellular therapy or active vacci- nation with approaches that maximize their antitumor activity by mitigating active pathways of immune sup- pression ...
5
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
... Tumor immunotherapy has changed the therapeutic landscape for patients with ...of tumor types [1, ...for Immunotherapy of Cancer (SITC) organized a Task Force on Cancer Immune Responsiveness ...
23
RNA Nanotechnology-Mediated Cancer Immunotherapy
... cancer immunotherapy treatments have drawn increasing ...by tumor cells, immunotherapeutics can inhibit the ability of tumor cells to evade termination by the immune system or re-program ...
19
Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer
... Based on the high quality of the data as reviewed by a special committee, four abstracts from young investiga- tors were selected for presentation during the presiden- tial abstract session, chaired by iSBTc/SITC ...
10
Membrane Forces and Key Protein Determinants of Hematopoietic Cell Function: Lamins and Myosin-II in Hematopoiesis and CD47 in Immunotherapy of Cancer
... In this study, we provide a mechanistic view of ADCC amplified by the loss of CD47 expression without adverse effects to anucleated PB cells. Compared with CD47 knockdown tumors, growth of tumors displaying normal levels ...
223
Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy
... She subsequently underwent a left radical nephrec- tomy and IVC thrombectomy through a chevron inci- sion. There were dense adhesions near the renal hilum and bulky lymphadenopathy which required en-bloc ligation of the ...
6
The association between human cytomegalovirus and glioblastomas: a review
... Human cytomegalovirus (HCMV) was reported in glioblastoma multiforme (GBM) over a decade ago and this finding has the potential to increase our understanding of the disease and it offers an alternative ...
13
Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment
... and tumor angiogenesis via the production of vascular endothelial growth factors (VEGFs) [21], creat- ing a physical barrier to therapeutic agents ...promote tumor progression by secreting IL-6, TGF-β, ...
23
RNA transfected dendritic cells in cancer immunotherapy
... human tumor antigens rec- ognized by T cells have generally been limited to studying ...a tumor-specific T-cell response and great- ly reducing the amount of tumor tissue needed for antigen ...
6
Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy
... Among the genes whose expression are impaired by the dele- tion of TET2 are PD-L1 and 3 Th1-type chemokine genes, CXCL9, CXCL10, and CXCL11. We demonstrated that IFN-γ stimulates TET2 binding to and increased 5hmC level ...
17
Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?
... of tumor growth, similar treatment modalities (surgery, radiation and chemotherapy), devastating impact on quality of life and dismal prognosis, the underlying disease pathogen- esis and interaction between ...
8
New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy
... the tumor suppressor p53 ( p53 or Trp53 ) ...ideal tumor associated antigen (TAA) for cancer ...to tumor regression and clearance, which were at least partially caused by the activation of innate ...
11